137 related articles for article (PubMed ID: 20821751)
1. You can win by losing: p53 mutations in rhabdomyosarcomas.
Post SM; Lozano G
J Pathol; 2010 Oct; 222(2):124-8. PubMed ID: 20821751
[TBL] [Abstract][Full Text] [Related]
2. p53 mutation and loss have different effects on tumourigenesis in a novel mouse model of pleomorphic rhabdomyosarcoma.
Doyle B; Morton JP; Delaney DW; Ridgway RA; Wilkins JA; Sansom OJ
J Pathol; 2010 Oct; 222(2):129-37. PubMed ID: 20662002
[TBL] [Abstract][Full Text] [Related]
3. Development of rhabdomyosarcoma in HER-2/neu transgenic p53 mutant mice.
Nanni P; Nicoletti G; De Giovanni C; Croci S; Astolfi A; Landuzzi L; Di Carlo E; Iezzi M; Musiani P; Lollini PL
Cancer Res; 2003 Jun; 63(11):2728-32. PubMed ID: 12782574
[TBL] [Abstract][Full Text] [Related]
4. p53 gene mutations and p53 protein expression in human soft tissue sarcomas.
Yoo J; Lee HK; Kang CS; Park WS; Lee JY; Shim SI
Arch Pathol Lab Med; 1997 Apr; 121(4):395-9. PubMed ID: 9140310
[TBL] [Abstract][Full Text] [Related]
5. Genomic analysis and preclinical xenograft model development identify potential therapeutic targets for MYOD1-mutant soft-tissue sarcoma of childhood.
Ting MA; Reuther J; Chandramohan R; Voicu H; Gandhi I; Liu M; Cortes-Santiago N; Foster JH; Hicks J; Nuchtern J; Scollon S; Plon SE; Chintagumpala M; Rainusso N; Roy A; Parsons DW
J Pathol; 2021 Sep; 255(1):52-61. PubMed ID: 34086347
[TBL] [Abstract][Full Text] [Related]
6. Adenovirus-mediated p53 gene therapy in pediatric soft-tissue sarcoma cell lines: sensitization to cisplatin and doxorubicin.
Ganjavi H; Gee M; Narendran A; Freedman MH; Malkin D
Cancer Gene Ther; 2005 Apr; 12(4):397-406. PubMed ID: 15618970
[TBL] [Abstract][Full Text] [Related]
7. Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice.
Ianzano ML; Croci S; Nicoletti G; Palladini A; Landuzzi L; Grosso V; Ranieri D; Dall'Ora M; Santeramo I; Urbini M; De Giovanni C; Lollini PL; Nanni P
Oncotarget; 2014 Jan; 5(1):108-19. PubMed ID: 24334679
[TBL] [Abstract][Full Text] [Related]
8. [Rhabdomyosarcoma development in Trp53/fos mutant mice: tumor suppressor functions of the Fos protooncogene].
Jochum W
Verh Dtsch Ges Pathol; 2004; 88():224-30. PubMed ID: 16892556
[TBL] [Abstract][Full Text] [Related]
9. Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function.
Keller C; Arenkiel BR; Coffin CM; El-Bardeesy N; DePinho RA; Capecchi MR
Genes Dev; 2004 Nov; 18(21):2614-26. PubMed ID: 15489287
[TBL] [Abstract][Full Text] [Related]
10. Mutation of the p53 gene in human soft tissue sarcomas: association with abnormalities of the RB1 gene.
Stratton MR; Moss S; Warren W; Patterson H; Clark J; Fisher C; Fletcher CD; Ball A; Thomas M; Gusterson BA
Oncogene; 1990 Sep; 5(9):1297-301. PubMed ID: 2216456
[TBL] [Abstract][Full Text] [Related]
11. Cooperation of oncogenic K-ras and p53 deficiency in pleomorphic rhabdomyosarcoma development in adult mice.
Tsumura H; Yoshida T; Saito H; Imanaka-Yoshida K; Suzuki N
Oncogene; 2006 Dec; 25(59):7673-9. PubMed ID: 16785989
[TBL] [Abstract][Full Text] [Related]
12. No correlation of c-myc overexpression and p53 mutations in liposarcomas.
Schneider-Stock R; Walter H; Rys J; Radig K; Hoang-Vu C; Roessner A
Virchows Arch; 1998 Oct; 433(4):315-21. PubMed ID: 9808433
[TBL] [Abstract][Full Text] [Related]
13. K-Ras and p53 mouse model with molecular characteristics of human rhabdomyosarcoma and translational applications.
Nakahata K; Simons BW; Pozzo E; Shuck R; Kurenbekova L; Prudowsky Z; Dholakia K; Coarfa C; Patel TD; Donehower LA; Yustein JT
Dis Model Mech; 2022 Feb; 15(2):. PubMed ID: 35174853
[TBL] [Abstract][Full Text] [Related]
14. Alterations of p53 gene in soft tissue and bone tumors.
Roessner A; Schneider-Stock R; Radig K; Neumann W; Mittler U
Gen Diagn Pathol; 1997 Jul; 143(1):1-13. PubMed ID: 9269903
[No Abstract] [Full Text] [Related]
15. Mutational status of K-ras and TP53 genes in primary sarcomas of the heart.
Garcia JM; Gonzalez R; Silva JM; Dominguez G; Vegazo IS; Gamallo C; Provencio M; España P; Bonilla F
Br J Cancer; 2000 Mar; 82(6):1183-5. PubMed ID: 10735503
[TBL] [Abstract][Full Text] [Related]
16. Mutation analysis of p53 gene in childhood malignant solid tumors.
Kusafuka T; Fukuzawa M; Oue T; Komoto Y; Yoneda A; Okada A
J Pediatr Surg; 1997 Aug; 32(8):1175-80. PubMed ID: 9269965
[TBL] [Abstract][Full Text] [Related]
17. Alternative splicing of Apoptosis Stimulating Protein of TP53-2 (ASPP2) results in an oncogenic isoform promoting migration and therapy resistance in soft tissue sarcoma (STS).
Tsintari V; Walter B; Fend F; Overkamp M; Rothermundt C; Lopez CD; Schittenhelm MM; Kampa-Schittenhelm KM
BMC Cancer; 2022 Jul; 22(1):725. PubMed ID: 35780096
[TBL] [Abstract][Full Text] [Related]
18. Targeting wild-type and mutant p53 with small molecule CP-31398 blocks the growth of rhabdomyosarcoma by inducing reactive oxygen species-dependent apoptosis.
Xu J; Timares L; Heilpern C; Weng Z; Li C; Xu H; Pressey JG; Elmets CA; Kopelovich L; Athar M
Cancer Res; 2010 Aug; 70(16):6566-76. PubMed ID: 20682800
[TBL] [Abstract][Full Text] [Related]
19. Pediatric nonrhabdomyosarcoma soft tissue sarcomas: progress on clinical and biologic fronts.
Wexler LH; Garvin JH
J Pediatr; 1997 Oct; 131(4):508-9. PubMed ID: 9386647
[No Abstract] [Full Text] [Related]
20. Immunohistochemical analysis for Mdm2 and p53 proteins in methylcholanthrene-induced mouse rhabdomyosarcomas.
Wu H; Inoue M
J Vet Med Sci; 2006 May; 68(5):427-31. PubMed ID: 16757884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
